 |
answer text |
<p>Results in the first 15 patients with systemic amyloidosis treated with a combination
of CPHPC and anti-SAP antibody have been published in the <em>New England Journal
of Medicine</em>. The phase I study is funded by GlaxoSmithKline (GSK) and the research
team includes researchers at University College London (UCL) and the National Amyloidosis
Centre (NAC).</p><br /><p>The National Institute for Health Research Clinical Research
Network (CRN) provides support to help the life sciences industry delivery high quality
commercial contract clinical research in the national health service. If a phase II
trial is developed, the CRN will work with GSK, the NAC and UCL as appropriate, to
deliver the trial.</p>
|
 |
